Verbinnen, Iris http://orcid.org/0000-0002-3681-1628
Monte-Boquet, Emilio http://orcid.org/0000-0001-5352-2601
Parow, Detlev
Lacombe, Fabienne
Pothecary, Andrew http://orcid.org/0000-0003-2297-4159
van Kuijk, Arno W. R.
Harrington, Laura
Müllerová, Edita
Pinter, Andreas http://orcid.org/0000-0002-1330-1502
Erstling, Ulrike http://orcid.org/0009-0000-3565-2410
Tomasini, Andrea
Helliwell, Philip S. http://orcid.org/0000-0002-4155-9105
Funding for this research was provided by:
UCB Pharma
Article History
Received: 15 December 2023
Accepted: 11 March 2024
First Online: 25 April 2024
Declarations
:
: Stakeholder leads (namely, Iris Verbinnen, Phillip S. Helliwell and Emilio Monte-Boquet) received an honorarium for their participation in the initial workshop and they and the other PsA CC members (Detlev Parow, Fabienne Lancombe, Andrew Pothecary, Arno W.R. van Kuijk, Edita Müllerová, Andreas Pinter, Ulrike Erstling and Andrea Tomasini) received an honorarium from UCB for their time to complete the Delphi e-consultations and to attend the PsA CC meeting or provide their input offline. UCB Pharma reviewed the manuscript to ensure scientific and medical clarity and accuracy only. Emilio Monte-Boquet has received grants/research support or participation in educational activities, research projects, scientific meetings (either attendance, speaking and/or delivering presentations) and advisory boards sponsored by Abbott/AbbVie, Amgen, Astellas, AstraZeneca, Baxalta, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chiesi, CSL Behring, Eisai, Fresenius, Galapagos, Gilead, GSK, Ipsen, Janssen, Leo Pharma, Lilly, MSD, Merck-Serono, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Theramex, UCB and ViiV. Detlev Parow has received an honorarium for advisory boards from Boehringer-Ingelheim, Hexal and UCB. Iris Verbinnen, Ulrike Erstling, Andreas Pinter, Edita Müllerová, Fabienne Lacombe, Andrea Tomasini and Arno W.R. van Kuijk have nothing to disclose. Laura Harrington is an employee of Ogilvy Health. Phillip S. Helliwell has received speaker fees from Novartis and participated in an advisory board for Amgen. Andrew Pothecary has received honoraria for lectures and educational events from AbbVie and Galapagos, for lectures and advisory boards from UCB Pharma and for advisory boards from Vifor Pharma and Thornton & Ross Ltd. Andrew Pothecary has also previously undertaken an unpaid volunteer position as an Expert Advisor at National Rheumatoid Arthritis Society (UK).
: This manuscript is formed of the opinions of the authors themselves. There was no need to collect any type of patient data. Therefore, the approval of an ethics committee was not required. Consent was obtained from all participants (or stakeholders).